Emerson Erik C. — SEC Form 4 filings
SEC reporting owner CIK 1710496. 3 Form 4 filings on record with FilingPulse; latest filed 2025-10-17.
Transaction summary — filings shown
Covers all 3 filings on record, filed 2024-01-18 to 2025-10-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | Chief Executive Officer, Director | 2 | — | — | 3 |
| Odyssey Health, Inc. (ODYY) | — | 1 | — | — | 1 |
Form 4 filings — Emerson Erik C.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-17 | 4 | Apimeds Pharmaceuticals US, Inc. (APUS) | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Apimeds Pharmaceuticals US, Inc. (APUS) | Grant/award (A): 750,000 @ $0 · Grant/award (A): 347,279 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Odyssey Health, Inc. (ODYY) | Grant/award (A): 37,500 (derivative) @ $0.09 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1710496 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →